Travere Therapeutics Names Bradley Campbell CEO as Eric Dube Steps Down
TVTX has more than doubled off its 52-week low of $22.055.
Summary
Travere Therapeutics announced CEO Eric Dube will step down December 1, 2026, with Bradley L. Campbell (former Amicus CEO) named as his successor. Campbell receives a $1M base salary, 85% target bonus, and approximately $20.25M in equity awards.
Key Events · Executive and Board Changes · TVTX
-
CEO Transition Announced
Effective December 1, 2026, Eric Dube will step down as President and CEO. Bradley L. Campbell, former President and CEO of Amicus Therapeutics, has been named his successor.
-
New CEO Compensation Package
Campbell will receive a $1M annual base salary, 85% target bonus, a $8.25M stock option, a $8.25M time-based RSU, and a $3.75M performance-based RSU in early 2027 — approximately $20.25M in total equity.
-
Transition Structure
Dube will serve as Executive Advisor through February 15, 2027, then as a consultant for up to 18 months. His 2026 bonus remains eligible; performance-based RSUs will cease vesting at separation.
-
Severance and Change-in-Control Terms
Campbell's agreement includes 1.5x salary-plus-bonus severance for termination without cause, and 2.0x for termination within 3 months before or 12 months after a change in control.
Analysis · TVTX · Life Sciences
A leadership change of this magnitude will shape strategy and execution for years, especially for a company with a ~$5.9 billion market cap. Travere Therapeutics is replacing its CEO: Eric Dube will step down as President and CEO effective December 1, 2026, and Bradley L. Campbell — former CEO of Amicus Therapeutics — will take over. The transition is structured to be orderly, with Dube staying on as Executive Advisor through February 15, 2027, then serving as a consultant for up to 18 months. Campbell's package is substantial — a $1 million base salary, 85% target bonus, and roughly $20.25 million in equity awards (a $8.25M option, $8.25M time-based RSU, and a $3.75M performance-based RSU in early 2027).
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVTX was trading at $62.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $22.06 to $68.73. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.